PCR (Phylasis Clinicas Research)

Belkins
Phylasis Clinicas Research S de RL de CV® (PCR) is a clinical research site in charge of supporting sponsors and CROs in the search for a competent and experienced research team. We know that the conduct of clinical studies plays an important role in the development of medications; and that the ethical conduct of the same, is the key to ensure high quality information that not only complies with the regulatory and research requirements; It also satisfies our moral responsibility to society. We work together with the pharmaceutical industry and medical specialists, facilitating interaction and ensuring confidentiality and responsibility.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

VALBIOTIS TEAMS UP WITH NESTLÉ TO REDUCE TYPE 2 DIABETES RISK

Labiotech | February 06, 2020

news image

In a deal worth up to €67M, industry giant Nestlé Health Science will have the global rights to commercialize Valbiotis’ food supplement for lowering the rate of type 2 diabetes in people at high risk of developing the condition. Under the terms of the deal, the French biotech will receive an upfront payment of €4.7M from Nestlé, along with up to €62M in undisclosed development and sales milestone payments. The proceeds from the partnership will let Valbiotis c...

Read More

RESEARCH

SKYE BIOSCIENCE ESTABLISHES NEW CANNABINOID PHARMACEUTICAL INNOVATION PROGRAM

Skye Bioscience, Inc. | October 13, 2021

news image

Skye Bioscience, Inc. (“Skye” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, has formed a new exclusive sponsored research agreement with Emerald Health Biotechnology Espana SLU (“EHBE”), focused on developing and characterizing novel molecules that can affect the endocannabinoid system (ECS) for therapeutic benefit. The research in...

Read More

MEDTECH

LIGAND PHARMACEUTICALS SELECTS LANDING AI'S LANDINGLENS VISUAL INSPECTION SOFTWARE PLATFORM TO ENHANCE THE ANTIBODY DISCOVERY PLATFORMS

Ligand Pharmaceuticals | July 29, 2021

news image

Landing AI announced today that it has entered into a software licensing deal with Ligand Pharmaceuticals Incorporated to integrate LandingLens into Ligand's OmniAb and xPloration antibody discovery platforms. LandingLens is a software platform that offers an end-to-end process for developing, experimenting and delivering AI-powered visual inspection solutions. The new AI-powered tools enhance Ligand's high-throughput single B cell screening accuracy and throughput in a wi...

Read More

MEDTECH

AVANTOR® WILL INCREASE GLOBAL PRODUCTION OF SINGLE-USE TECHNOLOGIES TO MEET THE BIOPHARMA DEMAND

Avantor | April 27, 2021

news image

Avantor Inc., a main worldwide supplier of crucial items and administrations to clients in the existing sciences, trend-setting innovations, and applied materials businesses, today declared that it will increment worldwide limit with regards to top-notch single-use advances utilized in the creation of biologics and antibodies. In the U.S. what's more, in Europe, the Company will build its single-use producing impression by 30% and twofold its cleanroom space. The speculation w...

Read More
news image

VALBIOTIS TEAMS UP WITH NESTLÉ TO REDUCE TYPE 2 DIABETES RISK

Labiotech | February 06, 2020

In a deal worth up to €67M, industry giant Nestlé Health Science will have the global rights to commercialize Valbiotis’ food supplement for lowering the rate of type 2 diabetes in people at high risk of developing the condition. Under the terms of the deal, the French biotech will receive an upfront payment of €4.7M from Nestlé, along with up to €62M in undisclosed development and sales milestone payments. The proceeds from the partnership will let Valbiotis c...

Read More
news image

RESEARCH

SKYE BIOSCIENCE ESTABLISHES NEW CANNABINOID PHARMACEUTICAL INNOVATION PROGRAM

Skye Bioscience, Inc. | October 13, 2021

Skye Bioscience, Inc. (“Skye” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, has formed a new exclusive sponsored research agreement with Emerald Health Biotechnology Espana SLU (“EHBE”), focused on developing and characterizing novel molecules that can affect the endocannabinoid system (ECS) for therapeutic benefit. The research in...

Read More
news image

MEDTECH

LIGAND PHARMACEUTICALS SELECTS LANDING AI'S LANDINGLENS VISUAL INSPECTION SOFTWARE PLATFORM TO ENHANCE THE ANTIBODY DISCOVERY PLATFORMS

Ligand Pharmaceuticals | July 29, 2021

Landing AI announced today that it has entered into a software licensing deal with Ligand Pharmaceuticals Incorporated to integrate LandingLens into Ligand's OmniAb and xPloration antibody discovery platforms. LandingLens is a software platform that offers an end-to-end process for developing, experimenting and delivering AI-powered visual inspection solutions. The new AI-powered tools enhance Ligand's high-throughput single B cell screening accuracy and throughput in a wi...

Read More
news image

MEDTECH

AVANTOR® WILL INCREASE GLOBAL PRODUCTION OF SINGLE-USE TECHNOLOGIES TO MEET THE BIOPHARMA DEMAND

Avantor | April 27, 2021

Avantor Inc., a main worldwide supplier of crucial items and administrations to clients in the existing sciences, trend-setting innovations, and applied materials businesses, today declared that it will increment worldwide limit with regards to top-notch single-use advances utilized in the creation of biologics and antibodies. In the U.S. what's more, in Europe, the Company will build its single-use producing impression by 30% and twofold its cleanroom space. The speculation w...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us